XEN907 is primarily researched for its potential therapeutic applications in the treatment of pain and neurological disorders. It functions as a selective sodium channel blocker, specifically targeting Nav1.7 channels, which play a crucial role in pain signaling pathways. By inhibiting these channels, XEN907 may help alleviate chronic pain conditions, such as neuropathic pain, where traditional painkillers are often ineffective. Its targeted mechanism offers the possibility of reduced side effects compared to broader-acting analgesics. Additionally, XEN907 is being explored for its potential in treating conditions like epilepsy and migraine, where sodium channel modulation is beneficial. Research is ongoing to fully understand its efficacy and safety profile in clinical settings.